Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ä«Å×°í¸®
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö (1468)
°Ô³ð â¾à (202)
¸ÂÃãÇüÀÇ·á (54)
¹ÙÀÌ¿À¸¶Ä¿ (154)
¹ÙÀÌ¿À¸ÅÆ®¸®¾ó (55)
¹ÙÀÌ¿ÀÀåºñ (323)
ºÐÀÚÇ¥ÀûÄ¡·á(MTT) (53)
À¯ÀüÀÚ Ä¡·á/RNAi (100)
Àç»ýÀÇÇÐ (125)
Ç×ü/¸é¿ª (187)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

Ç×ü/¸é¿ª ½ÃÀåÁ¶»çº¸°í¼­

Ç×ü/¸é¿ª ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.

»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 186 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Antiviral Therapeutics - technologies, markets and companies
»óǰÄÚµå :70939
°¢Á¾ Ç×¹ÙÀÌ·¯½º Ä¡·á ±â¼ú, ½ÃÀå µ¿Çâ, ±â¾÷ Á¤º¸ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Jain Pharmabiotech
ÆäÀÌÁö¼ö  
»ùÇÃ
»óǰÄÚµå :194071
¹éÇ÷º´ÀÇ ¾àÁ¦ °³¹ß Àü·«°ú ¾ÆÆ÷Åä½Ã½ºÀÇ ±â¼­¡¤Ç¥Àû¡¤¿µÇâ ºÐ¾ß ¹× Ç×üÀÇ È­ÇÕ¹° ¿µ¿ª¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4708 Pages
Triple Analysis: Prostate Cancer, Apoptosis and Antibodies
»ùÇÃ
»óǰÄÚµå :217037
Àü¸³¼±¾Ï ¾àÁ¦ °³¹ß Àü·«°ú ¾ÆÆ÷Åä½Ã½ºÀÇ ±â¼­¡¤Ç¥Àû¡¤¿µÇâ ºÐ¾ß ¹× Ç×ü È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4399 Pages
Triple Analysis: Pancreatic Cancer, Apoptosis and Antibodies
»ùÇÃ
»óǰÄÚµå :217023
ÃéÀå¾Ï ¾àÁ¦ °³¹ß Àü·«°ú ¾ÆÆ÷Åä½Ã½ºÀÇ ±â¼­¡¤Ç¥Àû¡¤¿µÇâ ºÐ¾ß ¹× Ç×ü È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4171 Pages
»ùÇÃ
»óǰÄÚµå :217015
Èæ»öÁ¾ ¾àÁ¦ °³¹ß Àü·«°ú ¾ÆÆ÷Åä½Ã½ºÀÇ ±â¼­¡¤Ç¥Àû¡¤¿µÇâ ºÐ¾ß ¹× Ç×ü È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4338 Pages
Triple Analysis: Breast Cancer, Apoptosis and Antibodies
»ùÇÃ
»óǰÄÚµå :217001
À¯¹æ¾Ï ¾àÁ¦ °³¹ß Àü·«°ú ¾ÆÆ÷Åä½Ã½ºÀÇ ±â¼­¡¤Ç¥Àû¡¤¿µÇâ ºÐ¾ß ¹× Ç×ü È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4474 Pages
»ùÇÃ
»óǰÄÚµå :216998
¾ÏÄ¡·áÁ¦ °³¹ß Àü·«¿¡¼­ ¾ÆÆ÷Åä½Ã½º ¹× ÇÁ·ÎÅ×ÀΠŰ³ª¾ÆÁ¦ ÀúÇØÁ¦ÀÇ ±â¼­¡¤Ç¥Àû¡¤¿µÇâ ºÐ¾ß ¹× Ç×ü È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 5003 Pages
Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies
»ùÇÃ
»óǰÄÚµå :216997
¾ÏÄ¡·áÁ¦ °³¹ß Àü·«¿¡¼­ ¾ÆÆ÷Åä½Ã½º ¹× ¾Ï¹é½ÅÀÇ ±â¼­¡¤Ç¥Àû¡¤¿µÇâ ºÐ¾ß ¹× Ç×ü È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4220 Pages
»ùÇÃ
»óǰÄÚµå :216996
¾Ï Ä¡·áÁ¦ °³¹ß Àü·«¿¡¼­ÀÇ ¾ÆÆ÷Åä½Ã½º(Apotosis)ÀÇ ±â¼­, Ç¥Àû, ¿µÇâ ºÐ¾ß¿Í Ç×ü(Antibody) ¹× ÆéƼµå(Peptide)ÀÇ È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4467 Pages
Triple Analysis: Apoptosis, Angiogenesis and Antibodies
»ùÇÃ
»óǰÄÚµå :216995
¾ÆÆ÷Åä½Ã½º(Apotosis) ¹× Ç÷°ü Çü¼º(Angiogenesis) ±â¼­, Ç¥Àû, ¿µÇâ ºÐ¾ß ¹× Ç×üÀÇ È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4788 Pages
Triple Analysis: Lung Cancer, Apoptosis and Antibodies
»ùÇÃ
»óǰÄÚµå :207613
Æó¾Ï(Lung Cancer)ÀÇ ¾àÁ¦ °³¹ß Àü·«, ¾ÆÆ÷Åä½Ã½º(Apoptosis)ÀÇ ±â¼­, Ç¥Àû, ¿µÇâ ºÐ¾ß ¹× Ç×ü(Antibodies)ÀÇ È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4884 Pages
»ùÇÃ
»óǰÄÚµå :195939
¸²ÇÁÁ¾ÀÇ ¾àÁ¦ °³¹ß Àü·«, ¾ÆÆ÷Åä½Ã½º(Apoptosis)ÀÇ ±â¼­, Ç¥Àû, ¿µÇâ¿¡ ÀÇÇÑ ¾àÁ¦ °³¹ß Àü·«¿¡ ÃÊÁ¡À» µÎ°í, ÆÄÀÌÇÁ¶óÀÎ Ä¡·áÁ¦ Æò°¡¹ý¿¡ ±Ù°ÅÇÑ Æò°¡¿Í ¾àÁ¦ °³¹ß Àü·«ÀÇ ºñ±³ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4515 Pages
Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies
»ùÇÃ
»óǰÄÚµå :177473
´ëÀå¾ÏÀÇ ¾àÁ¦ °³¹ß Àü·«°ú ¾ÆÆ÷Åä½Ã½ºÀÇ ±â¼­¡¤Ç¥Àû¡¤È¿°ú, Ç×üÀÇ È­ÇÕ¹° ¿µ¿ª, °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·«ÀÇ °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4617 Pages
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
»ùÇÃ
»óǰÄÚµå :224312
¼¼°è ´ÜÀÏ Å¬·Ð Ç×ü(Monoclonal Antibodies) ½ÃÀåÀÇ Ãֽе¿Çâ°ú ÇâÈÄ Àü¸Á¿¡ ´ëÇØ ºÐ¼®Çϰí, ÀüüÀû ½ÃÀå ±¸Á¶ ¹× µ¿Çâ, ÁÖ¿ä Áúȯº° ½ÃÀå µ¿Çâ ¹× Ãâ½Ã Á¦Ç°, ÀÓ»ó½ÃÇè, À¯¸Á ºÐÀÚ Á¤º¸, ÁÖ¿ä ±â¾÷ °³¿ä, ±â¾÷°£ Á¦ÈÞ, ÀÚº»°Å·¡ µ¿Çâ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 172
Competitor Analysis: Anti-Infective Antibodies
»ùÇÃ
»óǰÄÚµå :224082
ÀçÁ¶ÇÕ ´ÜÀÏŬ·ÐÇ×ü ¹× ´ÙÁßŬ·ÐÇ×ü(Recombinant Mono or polyclonal Antibodies), »ç¶÷ Ç÷Àå À¯·¡ ¸é¿ª±Û·ÎºÒ¸°(Human Plasma-derived Immunoglobulins)¿¡ °ü·ÃµÈ °¢ ±â¾÷¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÇöÀçÀÇ R&D °ü·Ã ÇÁ·ÎÁ§Æ® µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,086
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç La Merie Publishing
ÆäÀÌÁö¼ö 160 Pages
»ùÇÃ
»óǰÄÚµå :217040
¾Ï Ä¡·áÁ¦ °³¹ß Àü·«¿¡¼­ÀÇ ÇÁ·ÎÅ×ÀÎŰ³ª¾ÆÁ¦ ÀúÇØÁ¦(Protein Kinase Inhibitors)ÀÇ ±â¼­, Ç¥Àû, ¿µÇ⠺оß, Ç×ü(Antibody)ÀÇ È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4292 Pages
Triple Analysis: Prostate Cancer, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :217036
Àü¸³¼±¾Ï(Prostate Cancer) Ä¡·áÁ¦ °³¹ß Àü·«¿¡¼­ÀÇ Ç×ü(Antibody) ¹× ÆéƼµå(Peptide)ÀÇ È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 3688 Pages
Triple Analysis: Pancreatic Cancer, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :217022
ÃéÀå¾Ï(Pancreatic Cancer) Ä¡·áÁ¦ °³¹ß Àü·«¿¡¼­ÀÇ Ç×ü(Antibody) ¹× ÆéƼµå(Peptide) È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 3460 Pages
Triple Analysis: Melanoma, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :217013
Èæ»öÁ¾(Melanoma) Ä¡·áÁ¦ °³¹ß Àü·«¿¡¼­ÀÇ Ç×ü(Antibody) ¹× ÆéƼµå(Peptide)ÀÇ È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 3627 Pages
Triple Analysis: Cancer Vaccines, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :217007
¾Ï Ä¡·áÁ¦ °³¹ß Àü·«¿¡¼­ÀÇ ¾Ï¹é½Å(Cancer Vaccine)ÀÇ ±â¼­, Ç¥Àû, ¿µÇ⠺оß, Ç×ü(Antibody) ¹× ÆéƼµå(Peptide)ÀÇ È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 3509 Pages
Triple Analysis: Breast Cancer, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :217000
À¯¹æ¾Ï(Breast Cancer) Ä¡·áÁ¦ °³¹ß Àü·«¿¡¼­ÀÇ Ç×ü(Antibody) ¹× ÆéƼµå(Peptide) È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 3763 Pages
Triple Analysis: Angiogenesis, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :216992
¾Ï Ä¡·áÁ¦ °³¹ß Àü·«¿¡¼­ÀÇ Ç÷°ü Çü¼º(Angiogenesis) ±â¼­, Ç¥Àû, ¿µÇâ ºÐ¾ß¿Í Ç×ü(Antibody) ¹× ÆéƼµå(Peptide) È­ÇÕ¹° ºÐ¾ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °¢°¢ÀÇ ¾àÁ¦ Ç¥Àû Àü·«, È­ÇÕ¹° Àü·« °æÀï º¥Ä¡¸¶Å·, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4077 Pages
Triple Analysis: Lung Cancer, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :207639
Æó¾Ï(Lung Cancer)ÀÇ ¾àÁ¦ °³¹ß Àü·« ¹× Ç×ü(Antibodies), ÆéƼµå(Peptides)ÀÇ È­ÇÕ¹° Àü·«¿¡ ÃÊÁ¡À» ¸ÂÃß¾î, °¢°¢ÀÇ ¾àÁ¦ °³¹ß Àü·«, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 4173 Pages
Triple Analysis: Lymphoma, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :195951
¸²ÇÁÁ¾(Lymphoma)ÀÇ ¾àÁ¦ °³¹ß Àü·«, Ç×ü(Antibodies) ¹× ÆéƼµå(Peptides)ÀÇ È­ÇÕ¹° °³¹ß Àü·«¿¡ ÃÊÁ¡À» ¸ÂÃß¾î ÆÄÀÌÇÁ¶óÀÎ Ä¡·áÁ¦ Æò°¡¹ý¿¡ ±Ù°ÅÇÑ Æò°¡¿Í ¾àÁ¦ °³¹ß Àü·« ºñ±³ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 3804 Pages
Triple Analysis: Leukemia, Antibodies and Peptides
»ùÇÃ
»óǰÄÚµå :194069
¹éÇ÷º´ÀÇ ¾àÁ¦ °³¹ß Àü·«°ú Ç×ü ¹× ÆéƼµåÀÇ È­ÇÕ¹° Àü·«¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °¢°¢ÀÇ ¾àÁ¦ °³¹ß Àü·«, ÆÄÀÌÇÁ¶óÀÎ ¹× Æ÷Æ®Æú¸®¿À Ç÷¡´× µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,175
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 3997 Pages